This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Compared to Estimates, Chemours (CC) Q2 Earnings: A Look at Key Metrics

Chemours (CC) reported $1.59 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 1.5%. EPS of $0.42 for the same period compares to $0.58 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of -4.97%. The company delivered an EPS surprise of -2.33%, with the consensus EPS estimate being $0.43.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Thermal & Specialized Solutions: $591 million versus $666.16 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1% change.
Net Sales- Titanium Technologies: $661 million compared to the $661.68 million average estimate based on four analysts. The reported number represents a change of +0.6% year over year.
Net Sales- Other Non-Reportable Segment: $13 million compared to the $12.89 million average estimate based on four analysts.
Net Sales- Advanced Performance Materials: $326 million versus $333.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -5.8% change.
Adjusted EBITDA- Titanium Technologies: $48 million versus the four-analyst average estimate of $45.65 million.
Adjusted EBITDA- Thermal & Specialized Solutions: $213 million versus the four-analyst average estimate of $224.96 million.
Adjusted EBITDA- Advanced Performance Materials: $26 million versus $15.08 million estimated by four analysts on average.
Adjusted EBITDA- Other Non-Reportable Segment: $2 million versus the three-analyst average estimate of $2.69 million.

View all Key Company Metrics for Chemours here>>>

Shares of Chemours have returned -5.9% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Chemours Company (CC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research